Catherine Coste
CIK 1821432 · last filed 2026-10-08
Catherine Coste is a corporate insider who has filed 13 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for BLFS, was dated Oct 8, 2026. Across all open-market trades the lifetime net is +$56.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $29.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BMRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DANVILLE, CA 94526
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLFS | Director | 0 | $38.61 | $0 | $0 | 3 | 2026-10-08 |
| BMRA | Director | 17,237 | $1.71 | $29.5K | $56.1K | 7 | 2024-12-17 |
| Renalytix plc (RNLX) Delisted | Director | — | $0.21 | — | $0 | 2 | 2023-11-22 |
| MINERVA SURGICAL INC (UTRS) Delisted | Director | 6,479 | $0.00 | $1 | $0 | 1 | 2022-06-14 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-08 | BLFS | Disp (D) | −13,871 | $0 | EDGAR |
| 2026-02-26 | BLFS | Grant (A) | +8,170 | $0 | EDGAR |
| 2025-03-20 | BLFS | Grant (A) | +5,701 | $0 | EDGAR |
| 2024-12-17 | BMRA | Grant (A) | +85,000 | $26.4K | EDGAR |
| 2023-12-14 | BMRA | Grant (A) | — | $0 | EDGAR |
| 2023-12-11 | BMRA | Grant (A) | — | $0 | EDGAR |
| 2023-11-22 | Renalytix plc (RNLX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-07 | Renalytix plc (RNLX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-30 | BMRA | Buy (P) | +2,190 | $6.5K | EDGAR |
| 2022-06-14 | MINERVA SURGICAL INC (UTRS) Delisted | Grant (A) | +49,792 | $120.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.